Navigation Links
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
Date:11/6/2009

NEW YORK, Nov. 6 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Tuesday, November 10, 2009 at 8:30 a.m. EST to discuss the third quarter 2009 financial results and business outlook for the remainder of 2009. Ron Bentsur, Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call.

In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

The press release announcing the Company's financial results for this period will be posted on the Company's website, http://www.keryx.com, prior to the call.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed c
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
2. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
3. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
4. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
5. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
8. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Pa. , July 1, 2015 ... fully integrated specialty pharmaceutical company focused on developing, ... that Bob Radie , president and chief ... conferences this summer. He will provide an update ... (ketorolac tromethamine) Nasal Spray, approved product ...
(Date:7/1/2015)... July 1, 2015 New exchange plan enrollees ... 2015 compared to the same time a year ago, ... (NASDAQ: ESRX ) Exchange Pulse™ report, released today. ... 2014, the number of new exchange plan enrollees who ... in the first quarter of 2015. However, when evaluating ...
(Date:7/1/2015)... The Haselmeier Group has decided ... Gert Weber has been nominated by the Board ... Executive Officer (CEO) of the Haselmeier Group. This ... Mr. Weber brings more than 20 years of experience ... various executive management positions, the last being Managing Director ...
Breaking Medicine Technology:Egalet to Present at Upcoming Conferences This Summer 2Egalet to Present at Upcoming Conferences This Summer 3Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 2Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 3Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 4Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 5Haselmeier Group Announces the Extension and Reorganization of its Executive Board 2
(Date:7/1/2015)... ... July 01, 2015 , ... The 28th annual Charity ... shine Saturday, July 11, 2015, at 6 p.m. in Pugh Bourne Park, 343 Oakfield ... pony rides, a petting zoo, an Elvis impersonator, a silent auction and concessions. , ...
(Date:7/1/2015)... ... 01, 2015 , ... As if mood swings, cramps and child labor weren’t ... women: leg pain. Northeast Houston Vein Center is offering tips on the treatment options ... disease, is underdiagnosed and often overlooked. Many women experience the tiredness, achiness, restless legs, ...
(Date:7/1/2015)... ... July 01, 2015 , ... “Well-meaning social policy often ... Professor in FIU’s School of International and Public Affairs. , The ... in the National Survey on Drug Use and Health, which is a nationally ...
(Date:7/1/2015)... ... July 01, 2015 , ... RowdMap Inc. is a proud ... paper: “Pro-actively Identifying the High-Cost Patient Population: Insights from the Health Care Transformation ... http://www.hcttf.org/resouces-tools . , The Healthcare Transformation Task Force is a group of ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... solution provider of IBM software products, announced today that it has received trademark ... the integration, display and detailed analysis of data from multiple sources providing an ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 2Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 3Health News:Researchers find that medical marijuana laws increase recreational marijuana use among juveniles 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4
... juice, but not all experts agree with findings , , TUESDAY, ... fruit juices apparently don,t tend to be overweight, and they ... the beverages, a new study finds. , "We found juice ... A. Nicklas, a professor of pediatrics at Baylor College of ...
... June 3 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. ... "CSY"), a manufacturer,marketer and distributor of pharmaceutical, medicinal ... five of its products have,received production permit approvals ... China Sky One Medical began to develop products ...
... have long wrestled with how to aid those who ... to inject an artificial gel that can imitate cartilage,s ... But that solution is temporary, requiring follow-up injections. , ... a way to regenerate cartilage naturally by creating a ...
... David Hayes-Bautista and Linda Squires-Grohe Awarded $25,000 Each for ... ... Professions, SAN FRANCISCO, June 3 Three ... Health,Professions Diversity by The California Wellness Foundation (TCWF). Juanita,Barrena has played ...
... CHAPEL HILL, N.C., June 3 Market competition ... of the most qualified,clinical investigators. Field research shows ... 60-70% of the clinical trial,invitations that they receive ... are seeking better ways to manage the art,and ...
... 3 Burgess(TM) will be,a sponsor of ... most prominent,gatherings, held June 18th-20th in San ... and educational products,and services., A Burgess(TM) ... Health care: What are the New Data ...
Cached Medicine News:Health News:Fruit Juice May Be Healthy for Kids: Study 2Health News:Fruit Juice May Be Healthy for Kids: Study 3Health News:China Sky One Medical, Inc. Receives SFDA Approval for Five Patches 2Health News:China Sky One Medical, Inc. Receives SFDA Approval for Five Patches 3Health News:Brown researchers work toward ending cartilage loss 2Health News:Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award 2Health News:Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award 3Health News:Best Practice Toolkit Supports Recruitment of Top Clinical Investigators 2
... Simplex™ P with Tobramycin ... Bone Cement formula, with the ... By maintaining the original formula, ... performance characteristics of Simplex™ P ...
... Flow Analyzer is a fast, clinically proven ... of low and normal-tension glaucoma., ,The Ocular ... clinically proven measurement that improves detection of ... management of glaucoma, and detection of other ...
... Flexible Dosposable Easy Insertion/Removal ... (CSS) provides absolutely reliable support to ... thereby permitting routine phacoemulsification regardless of ... easy (similar to disposable iris retractors), ...
The collagen intracanicular plugs have a smooth proprietary finish that simplifies insertion of the plug. Collagen plugs are ideal for short term, diagnostic and post-surgical occlusion. Plugs are 2m...
Medicine Products: